Position in NVS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$162,570,671
+$154,587,680 QoQ
Shares Held
1,037,332
+1212.0% QoQ
Ownership
0.055%
of shares outstanding
% of Portfolio
0.38%
of 13F equity value
Holder Rank
#24
of 1,603 holders
Holding Since
Jun 2023
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Derivatives in NVS
reported options exposure · as of Jun 30, 2023CallValue
$156,410,500
CallShares
1,550,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Holocene Advisors, LP holds $1,328,883,667 across 8 Drug Manufacturers - General names. NVS ranks #4 (12.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AZN |
Astrazeneca PLC
|
2,429,349 | $460,653,157 | |
| 2 | GILD |
Gilead Sciences, Inc.
|
3,216,892 | $406,422,135 | |
| 3 | LLY |
ELI LILLY & Co
|
176,517 | $211,719,802 | |
| 4 | NVS |
Novartis AG
This page
|
1,037,332 | $162,570,671 | |
| 5 | MRK |
Merck & Co., Inc.
|
628,000 | $80,698,000 | |
| 6 | JNJ |
Johnson & Johnson
|
18,956 | $4,814,255 | |
| 7 | BIIB |
Biogen Inc.
|
4,793 | $1,035,575 | |
| 8 | ABBV |
AbbVie Inc.
|
3,855 | $970,072 |
All Filings in NVS
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $162,570,671 | 1,037,332 | Shares | Sole | 2026-08-14 | |
| 2023-12-31 | $7,982,991 | 79,063 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $24,814,012 | 243,609 | Shares | Sole | 2023-11-14 | |
| 2023-06-30 | $156,410,500 | 1,550,000 | Call | Sole | 2023-08-14 | |
| No filing history on record for this holder in this stock. | ||||||